v3.23.3
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:        
Revenue $ 723,126 $ 58,861 $ 2,146,804 $ 290,259
Operating expenses:        
Cost of revenues 545,023   1,540,454  
Research and development 5,155,359 5,379,780 16,600,186 13,334,021
Selling, general and administrative 6,082,539 4,838,169 19,603,075 13,299,474
In-process research and development impairment   3,500,000   3,500,000
Change in fair value of contingent consideration   (3,118,515)   (3,342,515)
Total operating expenses 11,782,921 10,599,434 37,743,715 26,790,980
Operating loss (11,059,795) (10,540,573) (35,596,911) (26,500,721)
Change in fair value of warrant liability   1,456   10,746
Other expense (income), net (110,352) 74,913 (329,103) 234,517
Unrealized (loss) gain on available-for-sale securities (36,116) (145,558) 99,437 (1,577,174)
Total non-operating loss (146,468) (69,189) (229,666) (1,331,911)
Net loss before income taxes from continuing operations (11,206,263) (10,609,762) (35,826,577) (27,832,632)
Income tax (expense) benefit   (37,063) 571,120 3,288,937
Net loss from continuing operations before income taxes (11,206,263) (10,646,825) (35,255,457) (24,543,695)
Net loss from discontinued operations before income taxes (3,040,577) (2,700,946) (5,848,220) (3,931,784)
Income tax (expense) benefit from discontinued operations (65,189)   (65,189)  
Net loss (14,312,029) (13,347,771) (41,168,866) (28,475,479)
Net loss - non-controlling interest (1,179,559) (89,421) (1,359,734) (265,256)
Net loss attributable to NightHawk Biosciences, Inc. $ (13,132,470) $ (13,258,350) $ (39,809,132) $ (28,210,223)
Net loss per share, basic - continuing operations (in dollars per share) $ (0.38) $ (0.41) $ (1.30) $ (0.95)
Net loss per share, diluted - continuing operations (in dollars per share) (0.38) (0.41) (1.30) (0.95)
Net loss per share, basic - discontinued operations (in dollars per share) (0.12) (0.11) (0.23) (0.15)
Net loss per share, diluted - discontinued operations (in dollars per share) (0.12) (0.11) (0.23) (0.15)
Net loss per share common share attributable to NightHawk Biosciences, Inc., basic (0.50) (0.52) (1.53) (1.10)
Net loss per share common share attributable to NightHawk Biosciences, Inc., diluted $ (0.50) $ (0.52) $ (1.53) $ (1.10)
Weighted-average common shares outstanding, basic (in shares) 26,050,562 25,613,316 26,022,244 25,603,481
Weighted-average common shares outstanding, diluted (in shares) 26,050,562 25,613,316 26,022,244 25,603,481
Comprehensive loss:        
Net loss $ (14,312,029) $ (13,347,771) $ (41,168,866) $ (28,475,479)
Unrealized gain on foreign currency translation 54,967 115,659 108,005 210,245
Total comprehensive loss (14,257,062) (13,232,112) (41,060,861) (28,265,234)
Comprehensive loss attributable to non-controlling interest (1,179,559) (89,421) (1,359,734) (265,256)
Comprehensive loss - NightHawk Biosciences, Inc. $ (13,077,503) $ (13,142,691) $ (39,701,127) $ (27,999,978)

Source